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15.1 Introduction to the endocrine system 
Hormones, produced by endocrine glands, are important in regulating and integrating the 
bodies functions. They have roles in metabolism, fluid balance, growth, development and 
reproduction. Hormones are chemical messengers released by glands. Hormones act 
specifically and at low concentrations on their target receptors, which are distant from the 
releasing organ. Hormones can be subdivided into classes based on their chemical structure; 
steroid hormones, amino-acid derived hormones and peptide hormones. There are differences 
in the release and activity of hormones depending on their chemical type (Table 15.1). 
 
The endocrine glands produce and release hormones into the bloodstream. They are usually 
transported by specialised hormone binding proteins. This increases the transport of the 
protein, decreases membrane transport (e.g. excretion in kidney, metabolism in liver, crossing 
of the blood brain barrier) and acts as a reservoir of the hormone in the blood. Only the 
unbound hormone can cross into cells and act at receptors. 
 
The hormone insulin and the treatment of diabetes and obesity are covered in Chapter 14.  
This chapter considers drugs used to treat thyroid disorders, osteoporosis and other bone 
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disorders, hyperparathyroidism, adrenal cortex disorders, infertility, and drugs that affect the 
hormones of reproduction 
 
 Peptide Hormones Steroid Hormones Amine Hormones 
Example Insulin, parathyroid 
hormone 
Oestrogen, 
androgens, cortisol, 
aldosterone 
Thyroxine 
Synthesis and storage Made in advance. 
Stored in secretory 
vesicles. 
Synthesised ion 
demand from 
precursors 
Made in advance. 
Precursor stored in 
secretory vesicles. 
Release from parent 
cell 
Exocytosis Simple diffusion Simple diffusion 
Transport in blood Dissolved in plasma Bound to carrier 
proteins 
Bound to carrier 
proteins 
Half-life Short Long Long 
Location of receptor Cell membrane Cytoplasm or 
nucleus. Some have 
cell membrane 
receptors 
Nucleus 
Signal transduction Activation of second 
messenger systems, 
activation of genes 
Activations of genes 
for transcription and 
translation. May have 
non-genomic activity 
Activations of genes 
for transcription and 
translation. 
General target 
response 
Modification of or 
initiation of protein 
synthesis 
Induction of new 
protein synthesis. 
Induction of new 
protein synthesis. 
 
Table 1: Characteristics of endocrine hormones 
 
15.2 Drugs used to treat disorders of the thyroid 
The thyroid gland is a butterfly-shaped gland located in the neck. It releases the hormone 
thyroxine (T4). There is a large circulating pool of thyroxine, which is metabolised to tri-
iodothyronine (T3) at the site of action. Normal thyroid function requires iodine (1-2 
g/kg/day). Thyroid disorders are relatively common and include hyperthyroidism and 
hypothyroidism. 
15.2.1 Hypothyroidism 
Congenital Hypothyroidism (often called cretinism) is most common preventable 
cause of mental retardation.  Hypothyroidism, which when it is severe is known 
as myxedema) is the most common disorder of thyroid function and is most often 
due to iodine deficiency, and is also known as primary hypothyroidism).  Some 
drugs cause hypothyroidism (e.g.  amiodarone , which is an iodine containing 
medicine of similar structure to the thyroid hormones). 
 
The symptoms of hypothyroidism are calorigenic such as a low basal metabolic 
rate low, decreased body temperature, and weight gain.  There are also central 
nervous system effects, which in the child, are mental and growth retardation, 
and in the adult, mental dulling, depression, memory impairment .  On the 
cardiovascular system, in hypothyroidism there is decreased activity of 
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sympathetic nervous system with low heart rate and heart pumping, leading to 
low blood pressure. 
Treatment of hypothyroidism is to use iodated table salt as prevention, which 
promotes the synthesis of the thyroid hormones.  In hypothyroidism, r eplacement 
therapy with thyroxine is used as treatment. 
 
15.2.3 Hyperthroidism 
Hyperthyroidism is elevated circulating thyroid hormone, and when the levels 
are very high the condition is known as thyrotoxicosis, a medical emergency.  
Graves’ disease, an autoimmune disease causing the excessive secretion of 
thyroid hormone, accounts for 60-90% cases of thyrotoxicosis.   
 
The symptoms or hyperthyroidism are calorigenic with a high basal metabolic 
rate, increased body temperature, and weight loss.  The central nervous system 
symptoms are irritability, restlessness, and insomnia.  On the cardiovascular 
system there is increased activity of sympathetic nervous system leading to a 
rapid heart rate and possible palpitations, and high blood pressure.  A unique 
feature is ophthalmopathy leading to exopthalmos, which is protrusion of the 
eyeballs 
 
Treatment for hyperthyroidism is drugs or surgery, or drugs prior to surgery. The 
drugs used include propylthiouracil, methimazole, iodide and radioactive iodine.  
Adjuvant treatment of hyperthyroidism is to treat the consequences of 
hyperthyroidism on the heart and includes β -adrenoceptor antagonist and Ca2+ 
channel blockers, which are discussed as cardiac drugs.  
 
Propylthiouracil or carbimazole are used in the treatment of hyperthyroidism, 
either to control Graves disease in anticipation of remission  or to control the 
hyperthyroidism prior to surgery.  Both of these drugs can be used in 
conjunction with radioactive iodine, to hasten recovery while awaiting the 
effects of radiation (discussed below).  Propiothiouracil inhibits 2 enzymes 
involved in the synthesis of the thyroid hormones; thyroid gland peroxidase and 
peripheral tissues iodothyronine 5
/
-deiodinase (Figure 15.1). Carbimazole only 
inhibits thyroid gland peroxidase (Figure 15.1). The incidence of side effects is 
relatively low with these drugs.  
 
High concentrations of iodide (6 mg day) are used pre-operatively, and in 
conjunction with propylthiouracil and propranolol in the treatment of thyrotoxic 
crisis.  High doses of iodide inhibit its own transport into thyroid gland, and 
therefore the synthesis of thyroxine.  Iodide inhibits the synthesis of 
iodotyrosines and iodothryonines, which are the precursors for the thyroid 
hormones, and this inhibition last about 2 days.  High dose iodide also inhibits 
the release of thyroid hormone.  
 
Radioactive iodine, 
131
I, emits both  rays and   particles, which accumulate in 
the thyroid gland and are cytotoxic.  Radioactive iodine and be used to 
selectively destroy some or all the thyroid gland, without affecting other tissues.  
This approach is used in hyperthyroidism.  
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Figure 15.1 Mechanism of action of propylthiouracil and carbimazole (Copyright 
QUT, Sheila Doggrell)  
 
 
15.3 Drugs used to treat osteoporosis and other bone disorders  
Osteoporosis is a skeletal disorder with compromised bone strength, and 
increased risk of fracture.  Osteoporosis is common in people who are  50 years 
old, with 1:2 women and 1:8 men having a fracture caused by osteoporosis.  
 
The causes of osteoporosis are multiple with physical, hormonal (predominantly 
low levels of oestrogens) and nutritional factors acting alone or together. The 
risk factors for osteoporosis are increasing age, being female, oestrogen 
deficiency, White race, low weight, family history, lack of exercise, alcohol 
abuse and smoking (especially in men).  
 
Primary osteoporosis often follows menopause in women, and occurs later in 
men.  Secondary osteoporosis is a result of medication, mainly glucocorticoids. 
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Osteoporosis is often described as a silent disease because initially there are no 
symptoms.  But eventually, it leads to stooped posture, loss of height (1 -2 inches 
due to multiple compression fractures of the spine), back pain and fractures.  
About half are spinal, a quarter is hip and a quarter is wrist fractures . 
 
The diagnosis of osteoporosis is by measuring Bone Mineral Density, BMD, and 
when BMD is 2.5 SDs below mean for young adult women, osteoporosis is 
diagnoses.  BMD is measured by DEXA (dual X-ray absorptiometry) which is 
scans of the spine, hip and arm to measure bone density  
 
15.3.1 Drugs used to treat osteoporosis  
For the prevention of osteoporosis, and to prevent fractures, calcium 
supplements and vitamin D are used.  For the  treatment of osteoporosis, drugs 
that decrease the loss of bone (raloxifene, bisphosphonates, denosumab) or 
increase acquisition of bone (strontium, teriparatide).   
 
Calcium supplements of 1,000/1,500 mg/day are recommended to prevent 
osteoporosis, and this is often combined with Vitamin D . Vitamin D is a mixture 
of cholecalciferol and ergocalciferol, hormones synthesized in skin requiring UV 
irradiation. Their primary active metabolite is calcitriol (1,25-
dihydroxycholecalciferol).  Calcitriol has a receptor-mediated role in calcium 
homeostasis whereby it facilitates the absorption of Ca
2+
 and phosphate from 
intestine, and decreases their excretion from kidney.  The standard dose of 
cilcitriol is 400-600 IU for adults. 
 
Hormone replacement therapy (HRT) , which is a mixture of progesterone and 
oestrogens, or oestrogen were previously used in the treatment of osteoporosis.  
This seems like a rationale treatment, as the problem underlying osteoporosis is 
often low levels of oestrogens.  However, there is some evidence that long -term 
treatment with HRT or oestrogens can increase the risk of breast and endometrial 
(uterine) cancer.  Thus, these agents are no longer used long-term in 
osteoporosis.  
 
Raloxifene is a partial agonist at oestrogen receptors.  On bone, this decreases 
the reabsorption of bone, to help maintain bone density.  Thus, raloxifene is used 
to prevent or treat postmenopausal osteoporosis.  Raloxifene acts to antagonize 
the effects of oestrogens on oestrogen receptors in the breast and endometrium.  
Thus, raloxifene reduces the risk of breast cancer, and is used for this in women 
who are at high risk of breast cancer.  
 
Presently, the most commonly used agents to prevent and treat osteoporosis are 
the bisphosphonates, such as alendronate and zoledronic acid .  The 
bisphosphonates inhibit the reabsorption of bone.  They have long half -lives, so 
that alendronate is effective when administered once-weekly and zoledronic acid 
can be administered intravenously once a year in subjects with severe 
osteoporosis.  Alendronate is used orally, but due to irritating the 
gastrointestinal tract, subjects need to remain upright for 30 minutes after taking.   
Bisphosphonates are also useful in the treatment of Paget’s di sease, where there 
are enlarged and misshapen bones.  
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Strontium is similar in structure to calcium, and can substitute for calcium in 
bone formation.  Thus, strontium increases bone mineral density and reduces the 
risk of fractures in subjects with osteoporosis. 
 
Parathyroid hormone has a major role in calcium homeostasis.  It increases 
calcium absorption from the gut, it increases calcium reabsorption from the 
kidney, and it stimulation of bone formation.  Thus, it is not surprising that 
teriparatide, the active fragment of parathyroid hormone is used in the 
treatment of osteoporosis, especially when there is a high risk of fractures and 
other agents are unsuitable.  Teriparatide is used subcutaneously.  In order for 
teriparatide to be effective, calcium is  needed.  Thus, teriparatide is used in 
subjects who are also receiving calcium supplements and Vitamin D.  
 
The newest agent available to treat osteoporosis is denosumab.  Denosumab 
binds to the RANKL ligand, which is involved in bone reabsorption.  By bin ding 
to the RANKL ligand, denosumab inhibits bone reabsorption.  Denosumab only 
needs to given subcutaneously every 6 months to be effective in the treatment of 
postmenopausal osteoporosis.  
  
15.4 Hyperparathyroidism 
Primary hyperparathyroidism (high secretion of the parathyroid hormone from 
the parathyroid glands) is a common endocrine disorder, especially in 
postmenopausal women.  It is usually caused by parathyroid adenoma (tumours) 
or spontaneous hyperplasia.  When there are high levels of parathyroid h ormone, 
there is increased resorption of calcium from bones, and increased absorption of 
calcium from the gastrointestinal tract and kidneys.  With high plasma levels of 
calcium and high urine phosphate levels, there can be renal stones, and bone pain 
leading to lesions and fractures.  Secondary hyperparathyroidism is associated 
with chronic renal insufficiency.   Surgery removing part of the parathyroid gland 
is probably the main treatment for hyperparathyroidism.  
 
Cinacalcet  is the drug used to treat hyperparathyroidism.  Cinacalcet increases 
the sensitivity of calcium-sensing receptors to calcium, which turns off the 
stimulus for parathyroid hormone secretion.  In addition to turning off 
parathyroid hormone secretion, cinacalcet inhibits parathyroid cell p roliferation 
and parathyroid hormone synthesis.  
 
15.5 Drugs used to treat adrenal cortex disorders 
The adrenal glands sit above the kidneys and comprise of 2 sub-sections the adrenal medulla, 
which produces catecholamines (adrenaline) and the adrenal cortex which synthesises the 
corticosteroids. Corticosteroids are involved in a wide range of physiologic processes 
including the stress response, immune response, regulation of inflammation, carbohydrate 
metabolism, protein catabolism, blood electrolyte levels, and behaviour. The adrenal cortex 
hormones are synthesised from cholesterol and released from the adrenal cortex and can be 
classed as glucocorticoids, mineralocorticoids or androgens.   
 
Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism and are 
anti-inflammatory, immunosuppressant and important for resistance to stress.  
Mineralocorticoids such as aldosterone control fluid and electrolyte balance, sodium and 
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water retention.  Androgens are the precursor of male and female sex hormones. These are 
important for the regulation of reproduction and the development of the sex organs. 
Cushing's syndrome (also known as hyperadrenocorticism or hypercorticism) is caused by 
elevated cortisol levels in the blood. Cushing's disease specifically involves a tumour 
(adenoma) in the pituitary gland that produces large amounts of adenocorticotrophic hormone 
(ACTH), which then elevates cortisol. The most common cause of Cushing's syndrome is 
exogenous administration of systemic glucocorticoids prescribed to treat other diseases 
(called iatrogenic Cushing's syndrome). Examples would include systemic glucocorticoid 
treatment for rheumatoid arthritis or for immunosuppression after an organ transplant.  
 
Symptoms include rapid weight gain, particularly of the trunk and face with sparing of the 
limbs (central obesity). Additional fat deposited on the back of the neck (buffalo hump) and a 
round or "moon face" is common. Other symptoms include excessive sweating, proximal 
muscle weakness (hips, shoulders) and hirsutism (due to increased androgen production), 
osteoporosis, amenorrhea, impotence diabetes mellitus and stunted growth. 
 
Addison’s disease (also known as adrenal insufficiency, hypoadrenalism, hypocortisolism) is 
a rare, chronic endocrine disorder in which the adrenal glands do not produce sufficient 
steroid hormones (glucocorticoids and mineralocorticoids). It is characterised by a number of 
relatively nonspecific symptoms, such as abdominal pain and weakness. Other symptoms 
include fatigue, postural hypotension, muscle pain and weakness, fever, weight loss, 
difficulty in standing up, anxiety, gastro-intestinal problems, headache, sweating, mood and 
personality changes. Causes of Addison’s disease include autoimmune damage of the adrenal 
gland, or a surgical bilateral adrenalectomy (due to tumour) or hypopituitarism, where 
insufficent ACTH is produced by the pituitary gland. Adrenal insufficiency may progress to 
Addisonian crisis, a severe illness resulting in marked hypotension and coma.  
 
Treatment for iatrogenic Cushing’s syndrome involves tapering down the glucocorticoid 
treatment causing the problem. Surgery is required to remove the tumour-related causes of 
Cushing’s syndrome. Removal of the adrenal glands would then require replacement with a 
glucocorticoid (e.g. cortisone) and a mineralcorticoid e.g. fludrocortisone.  Treatment of 
Addison’s disease also involves life-long replacement of adrenal hormones e.g. cortisone and 
fludrocortisone. 
 
The glucocorticoids are also used in the treatment of bronchial asthma (eChapter 17) and in 
the treatment of other inflammatory conditions.  The aldosterone antagonist spironolactone is 
used in the treatment of heart failure (eChapter 12). 
 
15.6 Drugs and the hormones of female reproduction 
 
15.6.1 Emergency contraception 
The ‘morning-after pill’ contains a high dose of levonorgestrel, which is progesterone-like 
(progestogen) drug.  Levonorgestrel inhibits the production of luteinizing hormone by the 
pituitary gland, which in turn prevents ovulation and fertilisation. The earlier oral 
levonorgestrel is taken the better, preferably within 3 days, but it can be effective up to 5 days 
after sexual intercourse.    
 
15.6.2 Contraception 
Most oral contraceptives contain an oestrogen-like drug (oestrogen) and a progestogen 
combined in various doses to mimic the 28-day menstrual cycle.  The oestrogen alone will 
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inhibit ovulation, but often leads to ‘break-through’ bleeding, which can be prevented by 
adding a progestogen.  The progestogen also decreases the production of luteinizing hormone 
to prevent ovulation and fertilisation.   
 
There are many combined oral contraceptive formulations available, but the most commonly 
used oestrogen is ethinyl-oestradiol. Progesterone itself is not used as a contraceptive as it is 
not active after oral administration.  Oral active progestogens commonly used in combined 
oral contraceptives formulations are low dose levonorgestrel and norethisterone.  Probably, 
the most serious adverse effects associated with combined oral contraceptives in an increased 
risk of thrombosis and myocardial infarction especially in smokers and women aged over 25 
years of age.  This increased risk is related to the oestrogen rather than progestogen part of 
the combined oral contraceptive. 
 
The ‘minipill’ is a progestogen-only oral contraceptive, which was designed for women with 
a history or thromboembolic disorders or who spoke. These progestogen-only contraceptives 
contain low dose levonorgestrel or norethisterone.  Without the oestrogen, there is a higher 
risk of ‘break-through’ bleeding. 
 
15.6.3 Other uses of oestrogens and progestogens 
The oestrogens are also used in disorders of menstruation (e.g. endometrial hyperplasia), in 
prostate cancer, and in hirsutism (excessive androgen-dependent hair growth).   
 
Oestrogens and progestogens are used together as hormone replacement therapy (HRT).  
HRT is a combination of a low dose of an oestrogen, such as oestradiol, and a progestogen, 
usually medoxyprogesterone acetate.  HRT can be used relatively safely for up to 5 years to 
relieve moderate-severe menopausal symptoms. The progestogen is mainly used to prevent 
endometrial cancer with the oestrogen. In women that have had a hysterectomy (removal of 
the uterus), oestrogen is safe and effective alone in preventing menopausal symptoms.  
 
15.7 Drugs for infertility 
The first drug used to treat female infertility is usually clomiphene.  The exact mechanism of 
action of clomiphene is not known, but it has anti-oestrogenic activity at the oestrogen 
receptors in the hypothalamus, which leads to reduced levels of follicle stimulating hormone 
and luteinizing hormone.  In turn, this leads to ovarian stimulation, maturation of the ovarian 
follicle, ovulation and development of the corpus luteum.  About 70% of women ovulate and 
30% conceive after clomiphene treatment. 
 
If clomiphene is unsuccessful in promoting fertility, a combination of hormones or drugs that 
mimic the effects of hormones, are used in sequence to promote the production of ovum for 
in-vitro fertilization, IVF (Figure 15.2). 
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Figure 15.2 Sequence of drugs used to produce ova for in-vitro fertilisation (Copyright QUT, 
Sheila Doggrell) 
 
15.8 Drugs and the hormones of male reproduction 
 
The main male sex hormone testosterone is used to treat androgen deficiency.  Androgen 
deficiency is associated with testicular failure caused by cryptorchidism (failure of one or 
both testes to descent into scrotum), orchitis (inflammation of the testes), orchidectomy 
(surgical removal of one or both testes).  Androgen deficiency can also be due to 
insufficiency of the pituitary-hypothalamic axis or in delayed male puberty. 
 
For a longer action, the enanthate ester of testosterone is used, and it is administered 
intramuscularly every 1-4 weeks.  Adverse effects are mainly related to route of 
administration, and with intramuscular can be bleeding, infection and extrusion. 
 
Androgens are anabolic agents stimulate the formation and maintenance of muscular and 
skeletal proteins.  For these reasons, the anabolic steroids have become drugs of abuse in 
sport but this is not discussed in this eChapter. 
 
Benign prostatic hyperplasia (BPH) is excessive growth of the prostate gland, which 
surround the urethra and obstructs the bladder to make urination difficult.  In severe prostatic 
hyperplasia, surgery to remove part or the entire prostate may be necessary.  Prior to this, 1-
adrenoceptor blocker such as prazosin or tamsulosin, which is the first example of an 
uroselective blocker, that is a selective 1-adrenoceptor blocker, which additionally shows 
selectivity for 1A-adrenoceptors (which are found on the prostate) over 1B-adrenoceptors, 
which are found of blood vessels. Tamsulosin is discussed in eChapter 7. 
 
The other drug used to treat BPH is finasteride, which is a 5α-reductase inhibitor.  In the 
prostate gland, testosterone is metabolised to 5α-dihydotestosterone, which is more potent 
than testosterone as an androgen, and promotes prostrate grown.  The enzyme responsible for 
this metabolism is 5α-reductase, and consequently inhibition of the enzyme with finasteride 
prevents the growth of the prostate.  
